Praxair filed a first petition for inter partes review of claims 1-19 of U.S. Patent 8,846,112.  The PTAB instituted review based on the first petition and concluded that all claims, except claim 9, were unpatentable.  In doing so, the PTAB determined that the “providing information” step in claim 1, and “similarly-worded claims steps in other